Developing a promising therapeutic technology which may contribute to treat various amyloidosis related diseases, incl. Alzheimer’s Disease. Venture Valuation (VV) interviewed TORII Shin-ichi, Ph.D., founder and CEO. Read the Interview Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Author: Venture Valuation
Heartseed Inc., Breakthrough cell therapy for severe heart failure.
As an innovative new treatment option for heart failure, a unique cardiac remuscularization therapy has been invented by Dr. FUKUDA Keiichi, Founder & CEO, Professor at Keio University School of Medicine. Venture Valuation (VV) interviewed YASUI Kikuo, COO. Read the Interview Would you like to be notified about new interviews, reports and other valuable content … Continue reading Heartseed Inc., Breakthrough cell therapy for severe heart failure.
How to assess start-up companies
Relevant soft factors to assess startup companies Investing in early-stage companies is a risky business. Many venture capitalists have fallen victim to the consequences of a myopic attitude towards thorough risk assessments. Although the negative experiences tend to be heard first, it’s the success stories that make it all the more worthwhile. Before taking the … Continue reading How to assess start-up companies
Yone Production Co. Ltd., Succeeded, on the world’s first attempt
Established by KOBAYASHI Yonesaku, a well-known documentary cameraman and pioneer of cinephotomicrography, and Dr ASAKA Tokio, anatomist and expert in biological sample research and development, Yone Production has played a vital role over 50 years in supporting scientific advancement and promoting scientific films. Venture Valuation (VV) interviewed FUJIEDA Ayumi, CEO. Read the Interview Would you … Continue reading Yone Production Co. Ltd., Succeeded, on the world’s first attempt
Resi Conference September 2021 – Company Valuation for Fundraising: Trends and Tools
Resi, virtual, September 2021, 31 pages Presentation Presentation
RESI Conference June 2021 – Company Valuation for Fundraising: Trends and Tools
RESI, virtual, June 2021, 31 pages Presentation Presentation
Workshop: Company Valuation for Fundraising – Trends & Tools
Venture Valuation held a workshop at the May 2021 edition of Biotechgate Digital Partnering, covering topics such as advice on speaking with investors and valuing a life science company with limited revenue – presented by Dr. Patrik Frei and Dr. Gergely Iványi on May 3rd, 2021. The full workshop can be viewed here, while slides … Continue reading Workshop: Company Valuation for Fundraising – Trends & Tools
Forty51 Ventures, newly established venture capital firm
April 2021: Started in Basel by three experienced Partners, Forty51 Ventures targets seed and early-stage investments in underfunded Biotech clusters in Switzerland, Germany, Eastern France, Northern Italy, and Austria. Venture Valuation (VV) interviewed Sascha Oliver Bucher, Co-Founder and Partner. Read the Interview Would you like to be notified about new interviews, reports and other valuable … Continue reading Forty51 Ventures, newly established venture capital firm
RESI Conference March 2021 – Product Valuation for Deal-Making
RESI, virtual, March 2021, 23 pages Presentation
RESI Conference March 2021 – Company Valuation for Fundraising: Trends and Tools
RESI, virtual, March 2021, 31 pages Presentation